ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1433

Identifying Predictors of Difficult-to-Manage Axial Spondyloarthritis: Real-World Insights from a Taiwanese Registry Cohort

Yen-An Chang and Ming-Han Chen, Division of Allergy, Immunology & Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, Taipei, Taiwan (Republic of China)

Meeting: ACR Convergence 2025

Keywords: Ankylosing spondylitis (AS), Disease Activity, Spondyloarthropathies

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (1405–1433) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: The concept of Difficult-to-Manage Axial Spondyloarthritis (D2M-ax-SpA) was recently introduced by the Assessment of Spondyloarthritis International Society (ASAS). According to this new definition, D2M-ax-SpA is characterized by (a) failure of ≥2 biologic or targeted synthetic DMARDs (b/tsDMARDs) with different mechanisms of action (MOAs), (b) persistent disease activity, and (c) symptoms considered problematic by either the patient or rheumatologist. This study is among the first to evaluate the real-world prevalence and clinical predictors of D2M-ax-SpA using this newly proposed definition.

Methods: We conducted a retrospective cohort study of patients with axial spondyloarthritis (ax-SpA) enrolled between January 2009 and December 2021 at Taipei Veterans General Hospital. Inclusion criteria included fulfillment of the ASAS classification criteria and ≥6 months of follow-up. Patients were categorized into three groups: D2M-ax-SpA (per ASAS definition), those treated with b/tsDMARDs with only one MOA, and those who never received b/tsDMARDs. Demographic, radiographic, and laboratory data were analyzed. Group comparisons were performed using the Mann–Whitney U and Fisher’s exact tests. Univariate and multivariate logistic regression were conducted to identify predictors of D2M-ax-SpA, and ROC curve analysis was applied to assess the predictive performance of laboratory markers.

Results: Among 560 patients with ax-SpA (all HLA-B27 positive), 20 (3.6%) met the criteria for D2M-ax-SpA. Ninety-four patients received b/tsDMARDs with a single MOA, while 446 were treatment-naïve to b/tsDMARDs. Compared to the other groups, patients with D2M-ax-SpA had significantly longer disease duration (median 3890 vs. 3292 and 2034 days, p< 0.01), more frequent peripheral arthritis (p< 0.01), higher grades of sacroiliitis on plain radiography (p< 0.01), and elevated ESR and CRP levels (p< 0.01). In multivariate analysis, peripheral arthritis emerged as an independent predictor of D2M-ax-SpA (OR: 4.68, 95% CI: 1.74–12.60, p=0.0022). ROC analysis demonstrated that ESR and CRP were strong predictive markers, each with an AUC of 0.785 (p< 0.0001), and optimal thresholds identified as ESR >20 mm/hr and CRP >0.99 mg/dL.

Conclusion: This study provides the first real-world evidence on the clinical characteristics and predictors of D2M-ax-SpA using the newly proposed ASAS criteria. Peripheral arthritis and elevated inflammatory markers (ESR, CRP) were strongly associated with treatment resistance. These findings highlight the importance of early identification of high-risk patients, which may inform treatment selection and improve long-term outcomes. Further prospective studies in larger, multi-ethnic cohorts are warranted to validate these results.

Supporting image 1Baseline Characteristics of the Axial Spondyloarthritis Cohort at Taipei Veterans General Hospital

Supporting image 2Univariate and Multivariate Logistic Regression Analysis Identifying Predictors of Difficult-to-Manage Axial Spondyloarthritis (D2M-ax-SpA)

Supporting image 3Receiver Operating Characteristic (ROC) Curve Analysis of Laboratory Markers Predicting D2M-ax-SpA


Disclosures: Y. Chang: None; M. Chen: None.

To cite this abstract in AMA style:

Chang Y, Chen M. Identifying Predictors of Difficult-to-Manage Axial Spondyloarthritis: Real-World Insights from a Taiwanese Registry Cohort [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/identifying-predictors-of-difficult-to-manage-axial-spondyloarthritis-real-world-insights-from-a-taiwanese-registry-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/identifying-predictors-of-difficult-to-manage-axial-spondyloarthritis-real-world-insights-from-a-taiwanese-registry-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology